Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor Therapy

NCT05529316 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT05529316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05529316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor Therapy
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 12, 2022
Completion date
February 29, 2028
Enrollment
150 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma